| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1222 | 2011 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15 Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, ... Blood 123 (24), 3750-3759, 2014 | 733 | 2014 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood 122 (17), 2965-2973, 2013 | 586 | 2013 |
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, ... Journal of Clinical Oncology 32 (8), 798, 2014 | 523 | 2014 |
| Molecular signatures of proliferation and quiescence in hematopoietic stem cells TA Venezia, AA Merchant, CA Ramos, NL Whitehouse, AS Young, ... PLoS biology 2 (10), e301, 2004 | 427 | 2004 |
| Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem … I Tzannou, A Papadopoulou, S Naik, K Leung, CA Martinez, CA Ramos, ... Journal of Clinical Oncology 35 (31), 3547, 2017 | 421 | 2017 |
| Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes CA Ramos, B Ballard, H Zhang, O Dakhova, AP Gee, Z Mei, M Bilgi, ... The Journal of clinical investigation 127 (9), 3462-3471, 2017 | 371 | 2017 |
| Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs S Ninomiya, N Narala, L Huye, S Yagyu, B Savoldo, G Dotti, HE Heslop, ... Blood 125 (25), 3905-3916, 2015 | 315 | 2015 |
| Side-effect management of chimeric antigen receptor (CAR) T-cell therapy ML Schubert, M Schmitt, L Wang, CA Ramos, K Jordan, C Müller-Tidow, ... Annals of oncology 32 (1), 34-48, 2021 | 306 | 2021 |
| Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, ... Journal of clinical oncology 38 (32), 3794, 2020 | 288 | 2020 |
| Clinical responses with T lymphocytes targeting malignancy-associated κ light chains CA Ramos, B Savoldo, V Torrano, B Ballard, H Zhang, O Dakhova, E Liu, ... The Journal of clinical investigation 126 (7), 2588-2596, 2016 | 288 | 2016 |
| Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue HG Kopp, CA Ramos, S Rafii Current opinion in hematology 13 (3), 175, 2006 | 263 | 2006 |
| Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy CA Ramos, G Dotti Expert opinion on biological therapy 11 (7), 855-873, 2011 | 258 | 2011 |
| In Vivo fate and activity of second-versus third-generation CD19-Specific CAR-T Cells in B Cell non-hodgkin’s lymphomas CA Ramos, R Rouce, CS Robertson, A Reyna, N Narala, G Vyas, B Mehta, ... Molecular Therapy 26 (12), 2727-2737, 2018 | 235 | 2018 |
| Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and … AA Kennedy-Nasser, S Ku, P Castillo-Caro, Y Hazrat, MF Wu, H Liu, ... Clinical Cancer Research 20 (8), 2215-2225, 2014 | 221 | 2014 |
| CAR-T cell therapy for lymphoma CA Ramos, HE Heslop, MK Brenner Annual review of medicine 67, 165-183, 2016 | 167 | 2016 |
| Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. CM Bollard, T Tripic, CR Cruz, G Dotti, S Gottschalk, V Torrano, ... Journal of clinical oncology: official journal of the American Society of …, 2018 | 160 | 2018 |
| CD19-CAR trials CA Ramos, B Savoldo, G Dotti Cancer journal (Sudbury, Mass.) 20 (2), 112, 2014 | 157 | 2014 |
| Tie2 activation contributes to hemangiogenic regeneration after myelosuppression HG Kopp, ST Avecilla, AT Hooper, SV Shmelkov, CA Ramos, F Zhang, ... Blood 106 (2), 505-513, 2005 | 131 | 2005 |
| Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization HG Kopp, AT Hooper, MJ Broekman, ST Avecilla, I Petit, M Luo, T Milde, ... The Journal of clinical investigation 116 (12), 3277-3291, 2006 | 123 | 2006 |
